The journey of a patent application in India does not end with filing. In many respects, it begins in earnest only when the Indian Patent Office issues what is formally known as the First Examination Report – the FER. For applicants who are new to the Indian patent system, the FER can appear daunting: a document that raises objections cites prior art, invokes statutory exclusions, and sets a clock running on the applicant’s response. For experienced practitioners, the FER is a familiar and navigable stage in prosecution, one that demands careful analysis, strategic thinking, and precise legal and technical argument. Understanding what the FER is, how it is generated, what it typically contains and how to respond to it effectively is among the most practically important bodies of knowledge for anyone engaged with the Indian patent system.
The FER is the first substantive communication from the Indian Patent Office to the applicant following examination of the application on its merits. It is not a rejection of the application. It is an examination report – a document that identifies the objections that stand between the application as filed and a grant of patent and invites the applicant to address those objections within a prescribed period. The distinction matters: an FER is an invitation to engage, not a final determination of patentability. Many applications that receive wide-ranging FERs ultimately proceed to grant following a well-crafted response. The skill lies in understanding the nature of each objection and responding to it with the combination of legal argument, claim amendment and technical explanation that the circumstances require.
The Statutory and Procedural Framework
The FER is issued under Section 12 of the Patents Act, 1970, which provides that when a request for examination has been filed, the Controller shall refer the application to an examiner for making a report. The examiner, after conducting a search and examining the application, prepares a report that the Controller then considers. If the Controller is satisfied, upon examination, that the application or the specification or any other document filed does not comply with the requirements of the Act or the rules, the Controller shall communicate the gist of the objections to the applicant and give the applicant an opportunity to be heard.
Rule 24B of the Patents Rules, 2003 governs the timeline for examination and response. A request for examination must be filed within 31 months from the priority date for applications filed under the Patent Cooperation Treaty or within 48 months from the date of filing or priority date, whichever is earlier, for ordinary applications. Once the request for examination is filed and the application becomes due for examination, the Patent Office is required to issue the FER within a prescribed period. Following the FER, the applicant has a period of six months from the date of the FER to file a written response – a period that is extendable by a further three months on request before the original period expires, subject to payment of the prescribed fee. The total outer limit for placing the application in order for grant is twelve months from the date of the FER, failing which the application is deemed to have been abandoned under Section 21(1) of the Act.
This twelve-month outer deadline is an absolute constraint. Unlike some other procedural timelines in Indian patent prosecution, it admits no discretionary extension beyond what the rules permit. Applicants and their representatives must be acutely aware of it from the moment the FER is received and must plan the prosecution strategy – the sequence and content of responses, hearing requests and further amendments – so that the application is placed in order for grant within that window.
The Content of the FER – What Examiners Typically Raise
A First Examination Report typically addresses several categories of objection and most FERs in practice raise more than one. Understanding each category is the foundation for an effective response strategy.
The most common category of objection concerns prior art and lack of novelty or inventive step. The examiner will have conducted a prior art search – typically using international databases, the Patent Cooperation Treaty search reports where available and the Indian Patent Office’s own resources – and will have identified documents that the examiner considers anticipate or render obvious the claimed invention. Anticipation objections assert that a prior art document discloses every element of the claimed invention and therefore destroys its novelty under Section 2(1)(l). Obviousness objections assert that the differences between the claimed invention and the prior art are such that a person skilled in the art would arrive at the invention without the exercise of any inventive step, within the meaning of Section 2(1)(ja). Prior art objections are the most technically demanding to respond to, requiring a careful comparison of each cited document against each claim under challenge.
The second major category concerns Section 3 exclusions. Depending on the subject matter of the application, the examiner may raise objections under one or more sub-clauses of Section 3 – most commonly Section 3(d) for pharmaceutical applications involving new forms of known substances, Section 3(k) for computer-implemented inventions and software-related applications, Section 3(c) for inventions that the examiner characterizes as mere discoveries or Section 3(j) for methods of treatment. Section 3 objections require a combination of legal argument and claim drafting strategy and in pharmaceutical cases particularly they are often the most consequential objections in the entire prosecution.
The third category involves formal and procedural objections: deficiencies in the specification or claims, ambiguities in claim language, failure to adequately disclose the best method of performing the invention, issues with the abstract, non-compliance with unity of invention requirements or deficiencies in the priority documents or sequence listings. Formal objections are generally more straightforward to address than substantive prior art or Section 3 objections, though they should not be underestimated – an inadequately responded-to formal objection can provide a basis for continued examination delay or refusal.
The fourth category, which arises in a significant number of FERs, concerns unity of invention under Section 10(5) of the Patents Act. The Act requires that a complete specification relate to a single invention or to a group of inventions so linked as to form a single inventive concept. Where the examiner considers that the application as filed claims multiple independent inventions – or inventions not linked by a single inventive concept – the FER will raise a unity objection and typically invite the applicant to elect which invention it wishes to prosecute in the current application, with the others to be pursued in divisional applications.
Reading and Analyzing the FER – The First Step
The first task upon receiving a FER is to read it with precision and systematic attention, not with alarm. Practitioners experienced in Indian patent prosecution will recognize that FERs frequently contain boilerplate objections, broadly framed citation characterizations and Section 3 objections raised as a matter of routine in certain technology sectors, regardless of the specific technical content of the application. This does not mean that FER objections should be taken lightly – it means that each objection must be assessed on its specific merits, not accepted at face value.
The analysis should begin with a careful mapping of each cited prior art document against the independent claims of the application. For each claim, the applicant or its representative should identify which elements of the claim the examiner contends are disclosed by the cited document and which elements – if any – are not disclosed. This claim-by-claim, element-by-element analysis forms the technical and legal foundation for the response. A document that discloses some but not all elements of a claim does not anticipate that claim; if the missing elements are not rendered obvious by the document alone or in combination with other cited art, novelty and inventive step can be defended.
The analysis of Section 3 objections requires a different approach. Here, the question is not whether the prior art discloses the invention but whether the invention, properly characterized, falls within an excluded category. For pharmaceutical Section 3(d) objections, the applicant must assess whether the claimed compound or form is a new form of a known substance within the meaning of the provision and if so, whether there is evidence of enhanced efficacy – typically pharmacological or clinical data – that can be placed before the Controller. For Section 3(k) objections to computer-implemented inventions, the applicant must identify the technical effect of the claimed invention and formulate arguments – and if necessary, amended claims – that present the invention in terms of its technical contribution rather than its abstract algorithmic character.
Responding to Prior Art Objections – Arguments and Amendments
The response to prior art objections in a FER takes one of two principal forms or a combination of both: arguments distinguishing the claims from the cited prior art and amendments to the claims that narrow their scope so as to avoid the cited art while preserving commercially meaningful protection.
Arguments without amendment are appropriate where the examiner has misconstrued the scope of the claims, misread the cited prior art or failed to appreciate a technical distinction that already exists on the face of the claims as filed. A well-crafted argument will identify, with precision, the element or combination of elements in the claim that is not disclosed by the cited document, explain why that element is not rendered obvious by the cited art either alone or in combination and do so in language that is technically accurate, legally grounded and clearly directed to the specific objection raised in the FER. Generic arguments that the invention is novel and inventive, without engagement with the specific cited documents, are unlikely to satisfy an examiner and will typically result in a hearing notice or a maintained objection.
Claim amendments are appropriate – and often necessary – where the claims as filed are genuinely anticipated by or obvious in light of the prior art, but where the specification discloses a narrower embodiment or a specific combination of features that is both patentable and commercially significant. Indian patent law permits claim amendments during prosecution, subject to the critical constraint of Section 59 of the Patents Act, which provides that no amendment shall be allowed that would introduce new matter – subject matter that is not disclosed in the specification as originally filed. This constraint is strictly applied. Amendments must find their basis in the specification as filed and any new feature introduced by amendment must be clearly supported by the original disclosure. The failure to observe this constraint can result in objections to the amended claims that are more damaging than the original prior art objections.
When amending claims in response to a FER, the applicant should also consider the potential implications of the amendment for the scope of protection ultimately granted. A narrowed claim that avoids the prior art but covers nothing of commercial value is, in practical terms, worthless. The goal of amendment strategy is to find the widest claim scope that is patentable over the prior art, not merely to achieve grant of the narrowest technically possible claim.
Responding to Section 3 Objections
Section 3 responses require the greatest degree of legal and technical sophistication in Indian patent prosecution. The approach depends critically on which sub-clause is invoked and the specific characteristics of the invention.
For Section 3(d) objections in pharmaceutical applications, the response must address two questions in sequence: first, whether the claimed compound is indeed a new form of a known substance within the meaning of the provision; and second, if it is, whether the applicant can demonstrate significantly enhanced efficacy. On the first question, there is sometimes scope for argument that the claimed compound is not merely a new form but a new chemical entity or that the parent compound is not a “known substance” within the relevant prior art context – arguments that require close engagement with the chemistry and the prior art. On the second question – enhanced efficacy the applicant must be prepared to place before the Controller documentary evidence of the relevant pharmacological, biochemical or clinical data. This is an evidentiary exercise as much as a legal argument and the quality and relevance of the data filed is determinative. Following the Supreme Court’s holding in Novartis, it is well-established that enhanced bioavailability alone is insufficient the applicant must demonstrate enhanced therapeutic efficacy, which typically requires in vivo data, clinical trial results or comparative pharmacological studies.
For Section 3(k) objections to computer-implemented inventions, the response should articulate the technical effect produced by the claimed invention with specificity, referencing the concrete technical result achieved and demonstrate that the invention, properly understood, is not merely a computer programme or algorithm in the abstract but a technical system or method that deploys computational means to achieve that technical result. Where the claims as filed are framed in a manner that is vulnerable to a per se characterization for instance, claims directed to the algorithm or software without reference to a specific technical application or hardware architecture amendment to introduce these elements, with supporting argument on technical effect, is the standard response strategy.
The Hearing – When and How to Request It
Following the applicant’s written response to the FER, the Controller will consider the response and, if satisfied that all objections have been addressed, will proceed towards grant. More commonly, particularly in technically complex applications or where Section 3 objections have been raised, the Controller will issue a hearing notice – a communication that identifies the objections that remain outstanding and fixes a date for a hearing at which the applicant may present oral arguments.
The hearing is an important opportunity and should be approached with careful preparation. The applicant or its representative appears before the hearing officer – typically a Controller or Deputy Controller of Patents – and presents oral arguments in support of the application’s patentability. The hearing is not merely a formality: it is an occasion at which the applicant can directly address the Controller’s residual concerns, provide technical explanations that may be difficult to convey through written submissions alone and make further amendments to the claims if necessary. Following the hearing, the Controller will typically either allow the application, maintain the objections and issue a further communication or in some cases refer the matter for further examination.
The applicant may also, instead of appearing personally or through a representative, submit written arguments in lieu of oral hearing. However, in applications where complex technical or legal questions are at issue – and particularly in pharmaceutical applications involving Section 3(d) – the oral hearing is generally the more effective avenue, since it allows for direct exchange and the opportunity to respond dynamically to the Controller’s concerns.
Common Errors in FER Responses and How to Avoid Them
Several patterns of error recur in FER responses filed by applicants, particularly those without experienced patent counsel. The most significant is the failure to respond to each objection in the FER with specific, directed argument – submitting instead a generic assertion of patentability that does not engage with the examiner’s specific citations or concerns. A response that does not address each cited document and each raised objection gives the Controller no basis to allow the application and will result in the objections being maintained.
A second common error is the failure to file claim amendments where the claims as originally drafted are genuinely vulnerable to the prior art cited in the FER. Applicants sometimes resist amendment out of a desire to preserve broad claim scope, without recognizing that a granted narrow claim is immeasurably more valuable than a refused broad one. The art of FER response is the art of calibrated compromise – finding the scope that is both commercially meaningful and legally defensible.
A third error is the failure to observe the twelve-month outer deadline. Prosecution in complex applications can extend through multiple rounds of response, hearing notices and further communications and it is possible for applicants – particularly those without experienced representation – to lose track of the running deadline. The consequences of allowing the twelve-month period to lapse are severe: the application is deemed abandoned and revival is subject to stringent conditions and is not always available.
The Working Statement Requirement – An Overlooked Obligation
A dimension of Indian patent prosecution that is frequently overlooked but legally significant is the obligation under Section 146 of the Patents Act to file a working statement – Form 27 – every financial year, disclosing whether the patented invention has been worked commercially in India during that year. While this obligation arises post-grant rather than during FER prosecution, it is worth noting in any comprehensive discussion of the Indian patent process because failure to file working statements has been used as a ground for compulsory licence applications and can affect the patent holder’s ability to resist such applications on the ground that the invention is being adequately worked.
Conclusion
The First Examination Report is not an obstacle – it is a structured conversation between the Patent Office and the applicant about whether the invention, as claimed, merits the grant of a patent under Indian law. Approached with preparation, precision and legal and technical rigour, it is a manageable and navigable stage in the prosecution process. The keys to an effective FER response are a systematic analysis of each objection on its specific merits, a clear-eyed assessment of the strength of the claims as filed against the cited prior art, a willingness to amend where amendment is necessary and strategically sound, a command of the relevant legal standards – particularly the standards under Section 3 that are most commonly in issue – and an unwavering attention to the procedural deadlines that govern the prosecution timeline.
India’s patent examination system has grown significantly in sophistication and capacity over the past decade, with reduced pendency periods and a more developed body of examination guidelines. For applicants seeking patent protection in India – whether domestic innovators, multinational corporations or research institutions – understanding the FER process in depth is not merely a matter of procedural knowledge. It is a strategic imperative that directly determines the quality and scope of the patent protection ultimately obtained.
References
- The Patents Act, 1970 – https://ipindia.gov.in
- The Patents Rules, 2003 – https://ipindia.gov.in
- Manual of Patent Office Practice and Procedure – https://ipindia.gov.in
- Guidelines for Examination of Computer Related Inventions, 2017 – https://ipindia.gov.in/writereaddata/Portal/IPOGuidelinesManuals/1_73_1_CRI_Guidelines_August_2015.pdf
- Novartis AG v. Union of India, (2013) 6 SCC 1 – https://main.sci.gov.in
- TRIPS Agreement, WTO – https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
- Indian Patent Office – Official Portal – https://ipindia.gov.in
- National IPR Policy, 2016, DPIIT – https://dpiit.gov.in
Compulsory Licensing Copyright Act Copyright Act 1957 Copyright Infringement Copyright Law Copyright Rules Deceptive Similarity Goodwill Indian IP Framework Indian Patent Law Indian Trademark Law Intellectual Property Law Inventive Step IP Law India Passing Off Patent Claims Patent Enforcement Patent Infringement Patent law Patent Revocation Patent Rule Pharmaceutical Patents Section 3 Section 29 The Patent Act 1970 Trademark Enforcement Trademark Registration Trade Marks Act 1999 Trade Marks Rules 2017 TRIPS Compliance